Ozempic vs. Wegovy: Which Does Medicare Cover?

Ozempic and Wegovy are two of the most talked-about GLP-1 medications, and they share the same active ingredient — semaglutide, made by Novo Nordisk. Despite that, Medicare treats them very differently. The difference comes down to what each drug is FDA-approved to treat, and Medicare Part D has historically paid for medical conditions rather than for weight loss alone. Understanding that distinction is the key to knowing which one your plan is likely to cover.

Ozempic is approved by the U.S. Food and Drug Administration to improve blood sugar in adults with type 2 diabetes, and it carries an additional approval to reduce the risk of major cardiovascular events in people who have type 2 diabetes and established heart disease. Wegovy uses a higher dose of the same semaglutide molecule and is approved for chronic weight management in adults and adolescents with obesity, and more recently to reduce cardiovascular risk in adults with established heart disease and obesity. You can confirm each drug's approved uses on FDA.gov.

That difference matters because, for many years, Medicare Part D was legally barred from covering drugs used solely for weight loss. So Ozempic — prescribed for diabetes — was routinely covered, while Wegovy — prescribed for weight loss — generally was not. The 2024 expansion that allowed coverage of semaglutide for cardiovascular risk reduction began to change that picture for a specific group of patients.

For Ozempic, the prior authorization is usually straightforward: your prescriber documents your type 2 diabetes diagnosis, often with a recent A1C lab value, and submits it to your plan. Because diabetes is a clearly covered indication, approvals are common when the paperwork is complete.

For Wegovy, the bar is higher. To get coverage under the cardiovascular pathway, your prescriber typically must document established cardiovascular disease — such as a prior heart attack, stroke, or diagnosed coronary artery disease — alongside a qualifying body-mass index. If your only reason for taking the drug is weight loss, most Part D plans will still deny it. Either way, a coverage decision is normally returned within 72 hours, or 24 hours if the request is expedited.

When either drug is covered, your out-of-pocket cost depends on your plan's formulary tier, your deductible, and where you are in the Part D payment phases. The cash price of these medications often exceeds $1,000 a month, but once a prior authorization is approved you typically pay only your plan's copay or coinsurance. Thanks to the Inflation Reduction Act, covered Part D drugs are also subject to an annual out-of-pocket cap — once you reach it, you pay nothing more for covered drugs for the rest of the year. Check the current cap amount on CMS.gov, and use our cost calculator for a personalized estimate.

The bottom line: if you have type 2 diabetes, Ozempic is usually the more reliably covered option. If your goal is weight management, coverage hinges on whether you also qualify under the cardiovascular indication. Compare the full list on our covered drugs page, and confirm everything with your own plan before assuming a drug is or is not covered.